Company profile
IMMUTEP Ltd
NASDAQ:IMMPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| EFTILAGIMOD ALFA | phase2 | — | 5 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06637865 | phase1 | recruiting | 2024-07-17 | 2026-08-31 | Immutep S.A.S. | A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy Volunteers |
| NCT00354861 | phase1 | completed | 2005-05-01 | 2005-11-01 | Immutep S.A.S. | A Randomized Phase I Study of a Hepatitis B Antigen Combined With IMP321 |
| NCT04252768 | phase1 | withdrawn | 2023-06-01 | 2025-06-01 | Immutep S.A.S. | A Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients to Test a New Schedule of Efti (IMP321, Eftilagimod Alpha) as Adjunctive to a Weekly Treatment Regimen of Paclitaxel |
| NCT04811027 | phase2 | completed | 2021-08-27 | 2024-03-11 | Immutep S.A.S. | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC |
| NCT03625323 | phase2 | completed | 2019-02-21 | 2022-06-02 | Immutep S.A.S. | Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC |
FDA applications (0)
No records yet.